Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of kpv peptide capsule in China. Welcome to wholesale bulk high quality kpv peptide capsule for sale here from our factory. Good service and reasonable price are available.
The core component of KPV Peptide Capsule is the KPV peptide, also known as Lysine Proline Valine, which is a tripeptide compound composed of three amino acids. Its chemical structure is unique, with a molecular formula of C ₁₈ H ∝₅ N ₅ O ₅ and a molecular weight of approximately 389.5 g/mol. KPV peptide, as an active fragment of alpha melanocyte stimulating hormone (α - MSH), has significant biological activity. KPV peptide naturally exists in the human body and is a part of alpha MSH hormone.
Alpha MSH is a hormone secreted by the anterior pituitary gland, which has multiple physiological functions such as regulating melanin production, immune response, and inflammatory response. KPV peptide, as an active fragment of α - MSH, can be prepared in large quantities through chemical synthesis to meet the needs of scientific research and clinical applications. Relatively stable at room temperature, but to ensure optimal activity, it is usually recommended to store at low temperatures ranging from -20 ℃ to -80 ℃. During transportation and storage, repeated freeze-thaw cycles and prolonged exposure to high temperatures should be avoided to avoid affecting its biological activity.
Our product
Additional information of chemical compound:
| Product Name | KPV Peptide | KPV Peptide Capsule |
| Product Type | Tablets | capsule |
| Product Purity | HPLC≥99.0% | ≥99% |
| Product Specifications | Customizable | Customizable |
| Product Package | Customizable | Customizable |
Our Products
α-MSH (11-13) (free acid)+. COA
 |
||
Certificate of Analysis |
||
|
Compound name |
α-MSH(KPV) | |
|
CAS No. |
67727-97-3 | |
|
Grade |
Pharmaceutical grade | |
|
Quantity |
Customized | |
|
Packaging standard |
Customized | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
|
Lot No. |
20260109001 |
|
|
MFG |
Jan 12th 2026 |
|
|
EXP |
Jan 8th 2029 |
|
|
Structure |
|
|
| TEST STANDARD | GB/T24768-2009 Industry. Stnndard | |
|
Item |
Enterprise standard |
Analysis result |
|
Appearance |
White or almost white powder |
Conformed |
|
Water content |
≤4.5% |
0.30% |
| Loss on drying |
≤1.0% |
0.15% |
|
Heavy Metals |
Pb≤0.5ppm |
N.D. |
|
As≤0.5ppm |
N.D. | |
|
Hg≤0.5ppm |
N.D. | |
|
Cd≤0.5ppm |
N.D. | |
|
Purity (HPLC) |
≥99.0% |
99.5% |
|
Single impurity |
<0.8% |
0.48% |
|
Residue on ignition |
<0.20% |
0.064% |
|
Total microbial count |
≤750cfu/g |
80 |
|
E. Coli |
≤2MPN/g |
N.D. |
|
Salmonella |
N.D. | N.D. |
|
Ethanol (by GC) |
≤5000ppm |
400ppm |
|
Storage |
Store in a sealed, dark and dry place at-20 degrees |
|
|
|
||
|
|
||
Innovation in Formulation Design and Core Technologies
1. Breakthrough in oral delivery system
KPV Peptide Capsule use enteric microsphere encapsulation technology to achieve precise drug release in the intestine through pH sensitive polymer materials such as Eudragit L100-55. The capsule shell is made of hydroxypropyl methylcellulose (HPMC) and chitosan composite, which has gastric acid tolerance (insoluble for 2 hours in pH<1.2 environment) and rapid small intestine disintegration characteristics (disintegration rate ≥ 95% in 15 minutes in pH 6.8 environment). This design solves the problem of low oral bioavailability of peptide drugs, and clinical data shows that its intestinal absorption rate is 3.2 times higher than traditional dosage forms.
2. Membrane Enhancement Technology
A new membrane penetration enhancer, lauroyl arginine ethyl ester (LAE), is added to the formulation, which interacts with the phospholipid bilayer of intestinal epithelial cell membrane to form a transient pore structure. In vitro permeability tests showed that LAE can increase the permeability of KPV peptide in Caco-2 cell monolayers by 2.8 times without damaging cell integrity.
3. Stability guarantee system
The capsule contents are in the form of freeze-dried powder, containing mannitol (5%) and trehalose (3%) as freeze-drying protectants, combined with 0.1% EDTA chelated metal ions. The accelerated stability test showed that after being stored at 40 ℃/75% RH for 6 months, the degradation rate of the main components was less than 2.1%, far below the 5% threshold required by the FDA. The packaging adopts double aluminum bubble cover technology, combined with nitrogen filling, to further isolate moisture and oxygen.
In addition, there are the following characteristics:
Formulation form
α-Melanotropin(11-13) Peptide are a type of pharmaceutical formulation that prepares α-Melanotropin(11-13) peptides into capsule form. Capsule formulations have the advantages of masking adverse drug odors, improving drug stability, and being easy to carry and take.
Quality control and purity
The production process of α-Melanotropin(11-13) Peptide must follow strict quality control standards to ensure the purity and activity of the product. Usually, the purity requirement for α-Melanotropin(11-13) peptides is over 99% to ensure their efficacy and safety.
Safety and tolerability
α-Melanotropin(11-13) Peptide have shown good safety and tolerability in clinical trials. Its adverse reactions mainly include mild gastrointestinal discomfort, headache, etc., and the incidence is relatively low. Most adverse reactions can resolve on their own after discontinuation and do not require special treatment.
Administration route and dosage
α-Melanotropin(11-13) Peptide are typically administered orally. The specific dosage needs to be adjusted according to factors such as the patient's condition, age, weight, etc. It is generally recommended to start with a low dose and gradually increase to an effective dose to reduce the occurrence of adverse reactions.
Inflammatory bowel disease (IBD) treatment
KPV Peptide Capsule have shown significant efficacy in the treatment of ulcerative colitis. Ulcerative colitis is a chronic non-specific inflammatory disease of the intestine, with a complex pathogenesis involving multiple aspects such as abnormal activation of the immune system and dysbiosis of the gut microbiota. The KPV peptide exerts anti-inflammatory effects through multiple mechanisms and has a positive therapeutic effect on patients with ulcerative colitis.From a pharmacological perspective, KPV peptides can inhibit the NF - κ B signaling pathway and MAPK pathway.
Such as TNF - α, IL-1 β, etc. The KPV peptide reduces the release of these pro-inflammatory factors by inhibiting this pathway, thereby alleviating intestinal inflammation.The MAPK pathway also participates in the regulation of inflammatory response, and the inhibitory effect of KPV peptide on it also helps alleviate inflammatory symptoms.In clinical trials, patients took 100mg KPV Peptide orally daily for 8 consecutive weeks, and their Mayo score significantly decreased. The Mayo score is an important indicator for assessing the severity of ulcerative colitis, including frequency of bowel movements, rectal bleeding, endoscopic findings, and overall physician evaluation.
Crohn's disease is a chronic inflammatory granulomatous disease of unknown etiology in the gastrointestinal tract, which can involve the entire digestive tract and exhibit segmental or jumping distribution. KPV Peptide also have certain value in the treatment of Crohn's disease.For patients with Crohn's disease, the combination of KPV Peptide and 5-ASA treatment can significantly improve clinical remission rates. 5-ASA is a commonly used medication for the treatment of Crohn's disease, exerting anti-inflammatory effects through mechanisms such as inhibiting prostaglandin synthesis and scavenging oxygen free radicals.
Meanwhile, combination therapy can also lower CDAI scores. The CDAI score is a commonly used indicator for evaluating the activity of Crohn's disease, covering multiple aspects such as the patient's general condition, abdominal pain, diarrhea, and complications. A decrease in score indicates that the patient's condition has been effectively controlled. In addition, combination therapy can also reduce the risk of intestinal fibrosis and stenosis. Intestinal fibrosis and stenosis are common complications of Crohn's disease, which can lead to serious consequences such as intestinal obstruction. The application of KPV Peptide can help prevent the occurrence of these complications.
Skin and mucosal inflammatory diseases
Psoriasis is a common chronic recurrent inflammatory skin disease, which is closely related to immune system abnormalities, genetic factors, environmental factors, and other factors. KPV peptide improves the skin symptoms of psoriasis patients by regulating the balance between Treg cells and Th17 cells, inhibiting the secretion of pro-inflammatory factors such as IL-17A.Treg cells and Th17 cells play important roles in the immune system, and their imbalance is related to the occurrence and development of various autoimmune diseases. In psoriasis patients.
KPV peptide can selectively activate Treg cells, inhibit the differentiation of Th17 cells, restore the balance between Treg cells and Th17 cells, and reduce the secretion of pro-inflammatory cytokines.
Clinical studies have shown that after 12 weeks of treatment with KPV Peptide, the improvement rate of PASI score in psoriasis patients reached 74%. The PASI score is a commonly used indicator to evaluate the severity and treatment effectiveness of psoriasis, including two aspects: lesion area and severity.
Oral ulcers and vaginal mucosal inflammation are common mucosal inflammatory diseases that cause pain and discomfort to patients. Local combination oral treatment with KPV Peptide can accelerate mucosal healing, reduce pain and recurrence.For patients with oral ulcers, KPV peptide may enhance mucosal repair ability by promoting the proliferation and migration of mucosal epithelial cells. Meanwhile, its anti-inflammatory effect can alleviate the inflammatory response of oral mucosa and relieve pain.
After using KPV Peptide, the patient's pain relief time was shortened to 2.8 days and the wound healing time was shortened to 5.6 days.
In the treatment of vaginal mucosal inflammation, KPV peptide can also exert anti-inflammatory and promote mucosal repair effects. It can regulate the local immune environment of the vagina, reduce the adhesion and invasion of pathogens, and promote the normal physiological function recovery of the vaginal mucosa. Combining oral and local treatment can improve treatment efficacy and reduce disease recurrence.
Intestinal barrier repair and functional improvement
KPV peptides play an important role in intestinal barrier repair. The intestinal mucosal barrier is an important defense line for the body to resist pathogen invasion and maintain internal environmental homeostasis. When the intestine is damaged by factors such as inflammation, infection, drugs, etc., the intestinal barrier function will be disrupted, leading to increased intestinal permeability. Pathogenic bacteria and toxins can easily enter the body, triggering systemic inflammatory reactions.
KPV peptide enhances the barrier function of intestinal mucosa by upregulating the expression of tight junction proteins such as Occludin and ZO-1.
Tight junction proteins are important structural proteins that maintain tight junctions between intestinal epithelial cells. Increased expression of these proteins can strengthen intercellular connections and reduce intestinal permeability. In addition, KPV peptides can promote the proliferation of intestinal crypt stem cells and accelerate mucosal regeneration. Intestinal crypt stem cells have the ability of self-renewal and multi-directional differentiation, and are key cells for intestinal mucosal repair and regeneration. KPV peptide can activate the proliferation signaling pathway of crypt stem cells, promote their proliferation and differentiation, thereby accelerating mucosal repair.
Radiation enteritis is a gastrointestinal complication caused by radiation therapy for malignant tumors in the pelvic, abdominal, or retroperitoneal regions. Patients often experience symptoms such as abdominal pain, diarrhea, and bloody stools, which seriously affect their quality of life. KPV Peptide have achieved certain results in the treatment of radiation-induced enteritis.
For patients with radiation enteritis, the use of KPV Peptide Capsule reduces the time for abdominal pain relief. This is because the anti-inflammatory effect of KPV peptide can alleviate the inflammatory response of intestinal mucosa, relieve the spasm of intestinal smooth muscle, and thus alleviate abdominal pain symptoms. At the same time, the frequency of diarrhea significantly decreased, indicating that KPV peptide helps restore normal intestinal function, reduce intestinal secretion and motility abnormalities.
FAQ
What are the benefits of KPV peptide?
Studies have shown that KPV can reduce inflammation in intestinal cells, preserve the gut lining, and help restore balance in the microbiome. It also appears to promote faster healing of damaged tissues and prevent the breakdown of the intestinal barrier, which is essential for maintaining overall gut health.
What is the difference between KPV and BPC?
BPC-157 vs KPV: a quick comparison;They are small, and they have been studied for inflammation and tissue repair. They may act through different pathways. BPC-157 is often framed around repair and blood flow, while KPV is framed around immune signaling.
Who should not use KPV peptide?
Additionally, like other therapeutic peptides, KPV is likely contraindicated for pregnant or breastfeeding women and people with a history of cancer.
Hot Tags: kpv peptide capsule, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, 3 6 dibromophenanthrene, CAS 1674334 59 8, tetracaine hcl powder, h3po4 phosphoric acid, 5 4 4 5 5 tetramethyl 1 3 2 dioxaborolan 2 yl spiro cyclohexane 1 9 fluorene 2 carbonitrile, Nitroso R salt